{"product_id":"orgs-vrio-analysis","title":"Orgenesis Inc. (ORGS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Orgenesis Inc. (ORGS) truly built for sustained success? Our deep-dive VRIO Analysis, distilled in the findings of \u0026amp;O4\u0026amp;, cuts straight to the core of its competitive edge, revealing precisely where its Value, Rarity, Inimitability, and Organization create lasting market dominance - or where vulnerabilities lie. Discover the critical factors underpinning Orgenesis Inc. (ORGS)'s strategic position by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 1. Decentralized POCare Manufacturing Platform (Octomera\/OMPULs)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Orgenesis Inc. (ORGS) and trying to figure out if their decentralized manufacturing bet, the POCare platform using OMPULs, is a real competitive edge or just a costly vision. Honestly, the numbers we have are mostly from late 2024, as the \u003cstrong\u003e2025\u003c\/strong\u003e fiscal year data isn't fully public yet - we’re waiting on that mid-November Q3 2025 release for the latest cash burn and revenue ramp. Still, the structure of their platform gives us a solid starting point for a VRIO assessment.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on their recent scale: As of September 30, 2024, the trailing twelve-month revenue was only about \u003cstrong\u003e$899K\u003c\/strong\u003e, against a net loss attributable to the company of \u003cstrong\u003e$55.36 million\u003c\/strong\u003e in the prior fiscal year 2023. That cash burn is real, but the value proposition hinges on the platform’s potential to slash the typical 18-to-24-month setup time for a cell therapy facility down to just \u003cstrong\u003e3-to-6 months\u003c\/strong\u003e. That speed is what could change the game for personalized therapies.\u003c\/p\u003e\n\n\u003cp\u003eWe can map out the VRIO dimensions for the OMPULs platform below. What this estimate hides, defintely, is the actual contract revenue generated by the platform in 2025 versus the cost to deploy and support the units.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment for OMPULs Platform\u003c\/th\u003e\n    \u003cth\u003eCompetitive Implication\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh. Enables lower-cost, faster, and more accessible production of personalized cell and gene therapies (CGTs) closer to the patient, overcoming centralized manufacturing bottlenecks.\u003c\/td\u003e\n    \u003ctd\u003eParity to Temporary Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eRelatively Rare. Claim of having the only existing global decentralized production platform with this specific, validated, closed-system capability against giants like Lonza.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh Imitability Hurdle. Replicating the validated, GMP-compliant hardware (OMPULs) and the operational workflow requires significant capital and regulatory validation time.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh. The company is structured around this model, using its subsidiary Octomera to drive this core business line, and recently reacquired full ownership to streamline focus.\u003c\/td\u003e\n    \u003ctd\u003ePotential for Sustained Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe key to a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e here is execution on the cost and speed promises. If Orgenesis Inc. can profitably scale this decentralized model, the cost and access advantage becomes a massive barrier for competitors stuck with traditional, centralized contract development and manufacturing organization (CDMO) models. For example, their ORG-101 CAR-T therapy showed an \u003cstrong\u003e82%\u003c\/strong\u003e complete response rate in adults, which, when paired with a lower production cost, is a powerful market offering.\u003c\/p\u003e\n\n\u003cp\u003eYou need to watch the following operational metrics closely as they report their Q3 2025 results:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNumber of active OMPUL deployments globally.\u003c\/li\u003e\n\u003cli\u003eRevenue per deployment\/licensing fee structure.\u003c\/li\u003e\n\u003cli\u003eCash burn rate relative to new funding secured.\u003c\/li\u003e\n\u003cli\u003eProgress integrating the March 2025 Neurocords acquisition.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 2. Proprietary 3D-V Technology Platform IP\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Licensed patents for 3D printing of cells and tissue, specifically targeting pancreatic islet transplants for Type 1 Diabetes (KT-DM-103) and chronic pancreatitis (KT-CP-203).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eDevelopment Status (as of latest report)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKT-DM-103\u003c\/td\u003e\n\u003ctd\u003eType 1 diabetes\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePre-clinical\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKT-CP-203\u003c\/td\u003e\n\u003ctd\u003eChronic pancreatitis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePre-clinical\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e 3D bioprinting exists, but this specific, exclusively licensed platform from the University of Louisville Research Foundation for islet transplantation is unique to Orgenesis.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe platform is based on exclusively licensed patents and technology from the University of Louisville Research Foundation (ULRF) related to revascularization and 3D printing of cell and tissue for transplant.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors would need to license or develop similar technology, which is complex and time-consuming.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe license agreement with ULRF stipulates royalties of \u003cstrong\u003e3.5% of sales\u003c\/strong\u003e and certain performance milestones.\u003c\/li\u003e\n\u003cli\u003eThe Company paid $40 thousand under its obligations to ULRF during the year ended December 31, 2021.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company has integrated this into its pipeline, but the focus seems split between this and the CGT platform.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company entered into convertible loan agreements in 2022 for an aggregate of $9.15 million.\u003c\/li\u003e\n\u003cli\u003eAs of April 15, 2024, the registrant had 34,338,782 shares of common stock outstanding.\u003c\/li\u003e\n\u003cli\u003eTrailing Twelve Month (TTM) revenue as of mid-2025 was approximately $0.90 million or $899K.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Value is contingent on successful clinical translation of the specific transplant applications.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMarket Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eYear\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal 3D Bioprinting Market Size (Estimated)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal 3D Bioprinting Market Projected Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 13.05 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2034\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal 3D Bioprinting Market CAGR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.84%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025 to 2034\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 3. ORG-101 (CD19 CAR-T) Clinical Data Package\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides strong, real-world efficacy data and a potentially favorable safety profile for a high-value oncology indication (B-ALL).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAdult Patients\u003c\/th\u003e\n\u003cth\u003ePediatric Patients\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplete Response (CR) Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e82%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e93%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSevere Cytokine Release Syndrome (CRS) Incidence\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe data is derived from a real-world study involving \u003cstrong\u003e233 patients\u003c\/strong\u003e treated at a leading hematology center in \u003cstrong\u003eChina\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The data set is unique due to its generation via the Company's decentralized model, utilizing a third-generation lentiviral vector with a proprietary CAR construct.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Replicating this specific trial data and safety profile requires running the same therapy in the same patient population.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. This data is crucial for attracting partners for clinical development and commercialization, which is a key part of their strategy. The Company plans to initiate its own Phase \u003cstrong\u003e1\/2\u003c\/strong\u003e clinical multicenter study at the General University Hospital of Patras in \u003cstrong\u003eGreece\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company announced these results while its stock was trading at \u003cstrong\u003e$0.70\u003c\/strong\u003e, up \u003cstrong\u003e0.77 percent\u003c\/strong\u003e on the Nasdaq.\u003c\/li\u003e\n\u003cli\u003eAt the time of the announcement, Orgenesis had a market capitalization of \u003cstrong\u003e$32.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe stock demonstrated a \u003cstrong\u003e39.38%\u003c\/strong\u003e increase over the last three months.\u003c\/li\u003e\n\u003cli\u003eHarley Street Healthcare Group intends to set up a Global Cancer Initiative through its joint venture with Orgenesis to support further clinical development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Data ages; sustained advantage depends on moving to Phase \u003cstrong\u003e3\u003c\/strong\u003e and eventual approval.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 4. Global POCare Network (Partnerships)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Foundation enabling harmonized development, production, and distribution of advanced therapies at the point of care.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Network includes Development and Service Centers in the United States, Belgium, Israel, and South Korea.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Relationship management built over time, evidenced by the funding transition from the sale of Masthercell for \u003cstrong\u003e$315 million\u003c\/strong\u003e in February 2020, yielding net proceeds of \u003cstrong\u003e$127 million\u003c\/strong\u003e to fund the POCare model shift.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Network supports the POCare Platform strategy, with subsidiaries focused on expansion and services in Belgium, Germany, Korea (where Orgenesis owns \u003cstrong\u003e94.12%\u003c\/strong\u003e), and Israel.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained through ecosystem establishment.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eAmount\/Count\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork\/Subsidiary Presence\u003c\/td\u003e\n\u003ctd\u003eDevelopment and Service Centers\u003c\/td\u003e\n\u003ctd\u003eUnited States, Belgium, Israel, South Korea\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubsidiary Ownership\u003c\/td\u003e\n\u003ctd\u003eOrgenesis Korea Co. Ltd. Ownership Stake\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e94.12%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Financial Context\u003c\/td\u003e\n\u003ctd\u003eMasthercell Sale Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$315 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Financial Context\u003c\/td\u003e\n\u003ctd\u003eMasthercell Net Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$127 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Reporting (As of 9\/30\/2022)\u003c\/td\u003e\n\u003ctd\u003eAccumulated Deficit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$117 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Reporting (9 Months Ended 9\/30\/2022)\u003c\/td\u003e\n\u003ctd\u003eNegative Operating Cash Flows\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Data (As of 3\/22\/2023)\u003c\/td\u003e\n\u003ctd\u003eShares of Common Stock Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27,493,123\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Valuation (As of 6\/30\/2022)\u003c\/td\u003e\n\u003ctd\u003eAggregate Market Value (Non-Affiliates)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$54,809,919\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSubsidiaries focused on POCare Network expansion and services include Orgenesis Services SRL (Belgium), Orgenesis Germany GmbH (CRO services), and Orgenesis Biotech Israel Ltd. (process development).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 5. Ranpirnase (Antiviral\/Topical RNase) Technology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A broad-spectrum ribonuclease enzyme targeting double-stranded RNA, developed for topical use against HPV (genital warts) and potentially systemic use against other viruses like HIV and SARS.\u003c\/p\u003e\n\u003cp\u003eRanpirnase demonstrated specific activity against HPV-11 \u003cem\u003ein vitro\u003c\/em\u003e with a selectivity index greater than \u003cstrong\u003e88\u003c\/strong\u003e. The Genital Warts market size in the 7MM + China was estimated at approximately \u003cstrong\u003eUSD 983 million\u003c\/strong\u003e in \u003cstrong\u003e2021\u003c\/strong\u003e. The total incident cases in the 7MM + China were approximately \u003cstrong\u003e1.4 million\u003c\/strong\u003e in \u003cstrong\u003e2021\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Volunteers in Phase I Study\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvaluable Participants\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Healing Achieved\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e25\u003c\/strong\u003e participants (\u003cstrong\u003e83.3%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Time to Clinical Healing\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e30\u003c\/strong\u003e days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eParticipants Discontinued due to Adverse Reactions\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e (\u003cstrong\u003e16.7%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. A specific, developed enzyme platform with existing topical formulation data is a distinct asset outside their main CGT focus.\u003c\/p\u003e\n\u003cp\u003eRanpirnase has been used extensively in Phase \u003cstrong\u003eIII\u003c\/strong\u003e oncology trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The specific formulation and development data are proprietary, though the underlying enzyme class is known.\u003c\/p\u003e\n\u003cp\u003eThe Phase I study involved topical application of three different formulations of \u003cstrong\u003e1 mg\/ml\u003c\/strong\u003e ranpirnase.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. It represents a distinct, non-CGT therapeutic vertical they can pursue via licensing or partnership.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eOrgenesis entered a Services Agreement with Therapeutics, Inc. to support development and planned Phase \u003cstrong\u003e2\u003c\/strong\u003e Clinical Study for External Genital Warts (EGW).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe planned Phase \u003cstrong\u003e2\u003c\/strong\u003e study was targeted for early \u003cstrong\u003e2021\u003c\/strong\u003e, building on existing data from a placebo-controlled phase \u003cstrong\u003e1\/2\u003c\/strong\u003e clinical study with \u003cstrong\u003e75\u003c\/strong\u003e subjects with EGW.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEGW is reported to have approximately \u003cstrong\u003e400,000\u003c\/strong\u003e new cases annually in the US alone.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Value depends on successful progression through late-stage trials for its primary indications.\u003c\/p\u003e\n\u003cp\u003eThe study provided clinical evidence supporting assessment in expanded clinical studies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 6. Neurocords SCI Assets\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Acquired intellectual property, development data, and product deliverables in the field of advanced regenerative medicine therapies for spinal cord injuries (SCI) as of March 2025. The global spinal cord injury treatment market size was valued at \u003cstrong\u003e$7.5 billion\u003c\/strong\u003e in 2023 and is projected to reach \u003cstrong\u003e$11.2 billion\u003c\/strong\u003e by 2031 according to Data Bridge Market Research.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. This is a recent, specific acquisition that immediately plugs them into a high-need, complex therapeutic area. The acquisition was completed on March 3, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors would need to acquire similar assets or spend years developing them from scratch. The transaction involved the issuance of \u003cstrong\u003e1,200,000 shares\u003c\/strong\u003e of common stock by Orgenesis Inc. in consideration for the purchased assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The integration of this new asset into the existing POCare\/Therapies structure is the key execution challenge now. The integration combines Neurocords' technology with Orgenesis's MIDA Technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage is in the first-mover position from the acquisition, which erodes as development progresses. As of March 14, 2025, Neurocords LLC held \u003cstrong\u003e1,200,000 shares\u003c\/strong\u003e, representing an \u003cstrong\u003e18.84%\u003c\/strong\u003e ownership stake in Orgenesis.\u003c\/p\u003e\n\u003cp\u003eThe acquired assets and transaction details are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetail\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Completion Date\u003c\/td\u003e\n\u003ctd\u003eMarch 3, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsideration (Shares Issued)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,200,000\u003c\/strong\u003e shares of common stock\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Transaction Value (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 Global SCI Treatment Market Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected 2031 Global SCI Treatment Market Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrgenesis TTM Revenue (as of 30-Sep-2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$899K\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe specific intellectual property and data acquired include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eProtocols, documentation, SOPs, data, and results related to skin biopsy processing and fibroblast culture.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResults, methods, techniques, formulations, and manufacturing records concerning the fibroblast cell bank establishment.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eQuality control assays performed or developed under the MSA.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eTechnology that differentiates induced pluripotent stem cells (iPSC) into spinal cord neurons.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eA three-month option to receive an assignment of the William Rice University Option Agreement dated November 24, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 7. Bioxome\/Synthetic Exosome Delivery System\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Technology utilizing synthetic exosomes\/extracellular vesicles to fuse with cell membranes and deliver therapeutic cargo, currently being developed for Kidney and Liver Disorders.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While exosomes are a hot area, having a validated synthetic system capable of specific cargo delivery is a specialized asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOrgenesis Consortium was awarded a \u003cstrong\u003e€1.5M EUR Grant\u003c\/strong\u003e from the Walloon Government in Belgium for the EXOFASTTRACK Project dedicated to accelerated development of multiple therapeutic exosomes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Developing a stable, scalable synthetic exosome platform requires specialized engineering expertise.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. It’s a distinct technology platform that can be leveraged across multiple therapeutic areas.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenues (Nine Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$734,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnding September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Nine Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNine months ending September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$204,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5,171 K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s an early-stage platform; sustained advantage depends on proving superior delivery efficiency over natural vesicles.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company secured an equity line of credit of up to \u003cstrong\u003e$5 Million\u003c\/strong\u003e from Williamsburg Venture Holdings.\u003c\/li\u003e\n\u003cli\u003eThe purchase price for shares under the equity line is set at \u003cstrong\u003e90%\u003c\/strong\u003e of the market price (average of two lowest VWAPs over five consecutive trading days).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 8. Transdifferentiation Technology (AIPs for Diabetes)\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eA regenerative approach to transform a patient's own liver cells into functional, glucose-responsive Artificial Islet Cells (AIPs), potentially offering a practical cure for Total Pancreatectomy patients.\u003c\/p\u003e\n\u003cp\u003eThe incidence of diabetes following Total Pancreatectomy (TP) is reported as \u003cstrong\u003e100 percent\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. The specific application of transdifferentiation to create functional, glucose-responsive AIPs, especially with Orphan Drug Designation, is rare. The FDA granted Orphan Drug Designation for Autologous Insulin Producing (AIP) cells for severe hypoglycemia-prone diabetes resulting from TP on June 17, 2019.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOrphan Drug Designation in the US qualifies for seven years of market exclusivity from the date of US marketing approval.\u003c\/li\u003e\n\u003cli\u003eIn the EU, authorized orphan medicines benefit from ten years of protection from market competition with similar medicines with similar indications once approved.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. This is highly specialized regenerative medicine science that is difficult to replicate, based on the patented transdifferentiation process developed from the work of Professor Sarah Ferber.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. The company has secured FDA Orphan Drug Designation, showing regulatory progress, but execution risk remains high. The company's structure includes a wholly owned subsidiary, Orgenesis Ltd., which exclusively licenses the technology from Tel Hashomer Medical Research Infrastructure and Services Ltd. (THM) in Israel.\u003c\/p\u003e\n\u003cp\u003eSelected Financial and Statistical Metrics (Latest Reported Quarter\/Period):\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eUnit\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.35\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(Millions of US $)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-9.12\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(Millions of US $)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPS (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-9.29\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e29.69\u003c\/strong\u003e million\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e36.05\u003c\/strong\u003e million\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt \/ Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e72.29%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares of Common Stock Outstanding (Historical)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24,820,756\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 30, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSustained. If successful, this represents a potentially curative therapy in a massive market (all patients post-TP develop diabetes), creating a strong moat. The technology aims to overcome issues of donor shortage, cost, and chronic immunosuppressive therapy associated with islet cell transplantation.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrgenesis Inc. (ORGS) - VRIO Analysis: 9. Ability to Secure Non-Dilutive Grant Funding\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eDemonstrated success in securing non-dilutive funding, including €3.5M EUR from the Walloon Government in Belgium, to fund R\u0026amp;D and platform expansion, conserving cash.\u003c\/p\u003e\n\u003cp\u003eThe company secured non-dilutive grants totaling €3.5M EUR from the Walloon Government in Belgium.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrant Source\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePurpose Focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWalloon Government (Belgium)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€3.5M EUR\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecentralized production of ATMPs and development of therapeutic exosomes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Innovation Council Pathfinder\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDevelopment of technologies for autologous induced pluripotent stem cells (iPSCs) production.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGreek Government (via JV)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e€32 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAccelerate development of Theracell's therapies utilizing OMPULs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate. Orgenesis has a track record of securing substantial, specific grants for its decentralized production technology.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecured €3.5M EUR from the Walloon Government.\u003c\/li\u003e\n\u003cli\u003eSecured €4 million EIC Pathfinder Grant.\u003c\/li\u003e\n\u003cli\u003eJV approved for up to €32 million from the Greek government.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate. Relies on strong scientific proposals and established relationships with regional government bodies.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eHigh. Finance team and R\u0026amp;D leadership are organized to pursue and win competitive funding opportunities.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eTemporary. Grant funding is episodic; it bridges gaps but does not replace sustainable revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516225118357,"sku":"orgs-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/orgs-vrio-analysis.png?v=1740202794","url":"https:\/\/dcf-model.com\/pt\/products\/orgs-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}